Last update 01 Nov 2024

Ezabenlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Mechanism
PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
Regulation-
Login to view timeline

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
myxoid MFHPhase 2-27 Jun 2024
Soft Tissue SarcomaPhase 2-27 Jun 2024
Anal canal squamous cell carcinomaPhase 2
KR
14 Sep 2020
Anus NeoplasmsPhase 2
KR
14 Sep 2020
Neoplasm MetastasisPhase 2
GB
12 Feb 2019
Neoplasm MetastasisPhase 2
US
12 Feb 2019
Neoplasm MetastasisPhase 2
CA
12 Feb 2019
Solid tumorPhase 2
GB
12 Feb 2019
Solid tumorPhase 2
CA
12 Feb 2019
Solid tumorPhase 2
US
12 Feb 2019
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
15
(wqgfzhnixo) = One pt experienced a DLT (Grade 2 pneumonitis) during the MTD evaluation period. qsepdspckj (oslzvlxscm )
Positive
14 Sep 2024
Phase 1/2
16
(Phase Ia/Ib)
(bgayrdamkz) = In patients who received brigimadlin 45 mg q3w in the Phase Ia/Ib monotherapy (n=140)/combination trials (n=74), the most common any-grade treatment-related adverse events (TRAEs) were nausea (67.9%/70.3%) and fatigue (53.6%/39.2%), respectively. eumnlhmdel (ofjaievywl )
Positive
09 Sep 2024
(Phase Ia/Ib)
Phase 1
41
(qbekogmfxy) = wuhnprmnzc xgiqunvvnd (shnmjisrwn )
Positive
23 Oct 2023
(qbekogmfxy) = xhfgqdarne xgiqunvvnd (shnmjisrwn )
Phase 1
8
(hrwtmbdvqy) = kickmfwgyi gbnohzrefy (laywibdqye )
Positive
24 Jan 2023
(otbinalvtk) = kxgbaajpyx tqchpnzybc (alhctpszif )
Phase 1
26
(odrcnfuasy) = uxaldccxsk jxifxexito (hnqgjbzqss )
Positive
02 Jun 2022
(odrcnfuasy) = wjwhycfins jxifxexito (hnqgjbzqss )
Phase 1
-
(tyoxfsccgg) = icusuvqkto vnnurpunes (uyakydmatd )
Positive
19 Jan 2022
(tyoxfsccgg) = omxesqlmex vnnurpunes (uyakydmatd )
Phase 2
30
(jtvknsanys) = lqquyiuhos ygoqzabces (oqmgxpkxrg )
Negative
19 Jan 2022
Phase 2
60
(locally advanced/metastatic gastric/gastroesophageal adenocarcinoma with ≥1 prior treatment (anti-PD-[L]1 naïve))
(ktxwoclxai) = itooqukxpd lhgjvfkmdk (cqtqlpxrmm )
Positive
16 Sep 2021
(any advanced/metastatic solid tumours (except non-squamous NSCLC or melanoma) with prior anti-PD-(L)1 treatment, which progressed following at least stable disease (SD) for ≥4 months)
(ktxwoclxai) = lweyljejiv lhgjvfkmdk (cqtqlpxrmm )
Phase 1
215
(irklahfsrp) = wdvpduegss ihguizgcyu (srjikijjqe )
Positive
16 Sep 2021
Phase 1
111
(zltniuafis) = jgspfhvlza ghezcgxsfx (tucjyzjbtw )
-
16 Sep 2021
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free